What is epigenetic editing and how does it reverse gene expression?
Epigenetic editing is a technique that changes how genes are expressed without altering the underlying DNA sequence. It works by adding or removing chemical tags—like DNA methylation or histone modifications—that control whether a gene is active or silent. Think of it like flipping a light switch: the wiring (DNA) stays the same, but the light (gene expression) can be turned on or off. This is fundamentally different from traditional gene editing (like CRISPR-Cas9), which cuts and permanently changes the DNA [6].
The most common tool for this is a modified CRISPR system called dCas9 (dead Cas9), which cannot cut DNA but can be fused with epigenetic effector proteins. For example, fusing dCas9 with a DNA methyltransferase (like DNMT3A) adds methyl groups to silence a gene, while fusing it with a demethylase (like TET1) removes methyl groups to activate a gene [6][7]. In one study, researchers used a dCas9-SunTag-DNMT3A complex to increase DNA methylation at a target gene in snail embryos, achieving a 50% success rate in the hatching snails [7]. This demonstrates that epigenetic editing can precisely and predictably alter gene expression in living organisms.
What are the main challenges and limitations?
Despite the promise, epigenetic editing faces several hurdles before it becomes a routine treatment. The most significant challenges are delivery, off-target effects, and long-term stability. Getting the editing tools into the right cells—especially in the brain—remains difficult [1][3]. For example, delivery to the central nervous system is a major obstacle for treating neurological disorders [1]. Off-target effects, where the epigenetic changes occur at unintended genomic locations, can cause unwanted side effects [2][5].
Another critical issue is that not all epigenetic edits are maintained long-term. Some genes do not 'remember' their new methylation state after the editing tool is gone, meaning the effect may fade over time [8]. This is particularly true for genes that are not actively dividing, where the epigenetic marks are not automatically copied during cell division. Researchers are working on 'hit-and-run' strategies, where a brief pulse of editing induces a stable change that persists without continuous treatment [4][7]. However, more work is needed to ensure that these changes are truly durable and safe for patients.
About These Sources
This answer is built on 9 peer-reviewed studies — published from 2022 to 2026, 5 from 2024 or later, 6 in Q1 journals, collectively cited 175 times — selected as the most relevant from 12 studies that passed quality screening, drawn from 46 papers retrieved from a database of over 500 million.
Sources used in this answer
Precision epigenetic editing: Technological advances, enduring challenges, and therapeutic applications
This review catalogs existing epigenetic editing tools and their therapeutic applications, noting that delivery challenges, particularly to the brain, currently impede clinical translation, but predicts that with advances in engineering and delivery, epigenetic editing will become a powerful treatment for many disorders.
Epigenetic reprogramming as a therapeutic strategy for neurodegenerative diseases: A complex and novel approach
This review highlights that epigenetic reprogramming using CRISPR-dCas9, synthetic transcription factors, and Yamanaka factors can restore normal gene function in Alzheimer's, Parkinson's, and Huntington's disease models, but notes challenges including off-target effects, delivery limitations, and long-term safety concerns.
Epigenetic editing: from concept to clinic
This review reports that epigenetic editing has moved from concept to clinic, with successes in animal models of various diseases and the first clinical trials initiated, though straightforward guidelines for sustained expression modulation are still lacking.
Epigenetic Editing in Neurological and Neuropsychiatric Disorders: Pioneering Next-Gen Therapeutics for Precision Gene Control
This review describes how CRISPR/dCas9, zinc-finger proteins, and TALEs fused to epigenetic effectors can modify DNA methylation and histone marks at specific loci in neurological and neuropsychiatric disorders, and analyzes 'hit-and-run' editing and nanoparticle delivery as translational strategies.
Toward the Development of Epigenome Editing-Based Therapeutics: Potentials and Challenges
This review discusses the potential of epigenome editing for treating genetic and imprinted diseases, emphasizing the need to improve target specificity, enzymatic activity, and drug delivery, and introduces chromatin plasticity as a key factor for effective therapy.
CRISPR- based epigenetic editing: A new era of disease control without gen, A review
This review describes CRISPR-based epigenetic editing using dCas9 fused to epigenetic effectors as a safer, reversible alternative to genome editing, with potential applications in cancer, neurological disorders, cardiovascular diseases, and metabolic syndromes.
Hit-and-Run Epigenetic Editing for Vectors of Snail-Borne Parasitic Diseases
This study demonstrated in vivo methylome engineering in the snail Biomphalaria glabrata using a dCas9-SunTag-DNMT3A complex, achieving increased CpG methylation at the target site in 50% of hatching snails, showing that epigenetic editing works in invertebrates.
Gene-Targeted DNA Methylation: Towards Long-Lasting Reprogramming of Gene Expression?
This review finds that while epigenetic editing can successfully modulate gene expression in vivo, not all genes maintain their (de)methylation signatures after editing, and that multi-effector approaches may be needed for long-lasting reprogramming.
Drug repurposing in psoriasis, performed by reversal of disease-associated gene expression profiles
This study developed a computational drug repurposing framework that identified drugs capable of reversing psoriasis-associated gene expression signatures, validating 50 out of 150 top-ranked drugs in one dataset and 37 out of 150 in another as having anti-psoriasis efficacy.